222 related articles for article (PubMed ID: 16701150)
1. Bacillus Calmette-Guerin, Mycobacterium bovis, as an immunomodulator in atopic diseases.
Barlan I; Bahceciler NN; Akdis M; Akdis CA
Immunol Allergy Clin North Am; 2006 May; 26(2):365-77, ix. PubMed ID: 16701150
[TBL] [Abstract][Full Text] [Related]
2. Recombinant Mycobacterium bovis BCG.
Bastos RG; Borsuk S; Seixas FK; Dellagostin OA
Vaccine; 2009 Nov; 27(47):6495-503. PubMed ID: 19720367
[TBL] [Abstract][Full Text] [Related]
3. Consequence of prior exposure to environmental mycobacteria on BCG vaccination and diagnosis of tuberculosis infection.
Thom M; Howard C; Villarreal-Ramos B; Mead E; Vordermeier M; Hope J
Tuberculosis (Edinb); 2008 Jul; 88(4):324-34. PubMed ID: 18329343
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of bovine cutaneous delayed-type hypersensitivity (DTH) to various test antigens and a mitogen using several adjuvants.
Hernández A; Yager JA; Wilkie BN; Leslie KE; Mallard BA
Vet Immunol Immunopathol; 2005 Mar; 104(1-2):45-58. PubMed ID: 15661330
[TBL] [Abstract][Full Text] [Related]
5. The lack of relationship between serum content of MBL, sCD14, anti-PPD and anti-Hsp65 IgG and ingestion of Mycobacterium bovis BCG bacilli by phagocytes.
Paziak-Domańska B; Bonar A; Kowalewicz-Kulbat M; Klink M; Kowalski M; Karhukorpi J; Karttunen R; Jurkiewicz M; Rózalska B; Rudnicka W
Arch Immunol Ther Exp (Warsz); 2002; 50(5):337-44. PubMed ID: 12455868
[TBL] [Abstract][Full Text] [Related]
6. Mucosal immunization with recombinant heparin-binding haemagglutinin adhesin suppresses extrapulmonary dissemination of Mycobacterium bovis bacillus Calmette-Guérin (BCG) in infected mice.
Kohama H; Umemura M; Okamoto Y; Yahagi A; Goga H; Harakuni T; Matsuzaki G; Arakawa T
Vaccine; 2008 Feb; 26(7):924-32. PubMed ID: 18192091
[TBL] [Abstract][Full Text] [Related]
7. Systemic antitumor activity of Bacillus Calmette Guerin and purified protein derivatives against tumors in mice having tuberculin allergy.
Abe S; Saito M; Yamazaki M; Mizuno D; Tsumita T
Jpn J Exp Med; 1978 Oct; 48(5):455-7. PubMed ID: 372638
[No Abstract] [Full Text] [Related]
8. Mammary tumor growth inhibition in C3H/He mice by long-term Bacillus Calmette-Guérin immunoprophylaxis versus enhancement by primary Bacillus Calmette-Guérin therapy.
Vaage J
Cancer Res; 1983 Dec; 43(12 Pt 1):5778-82. PubMed ID: 6357431
[TBL] [Abstract][Full Text] [Related]
9. New insights into the effects of Mycobacterium bovis Bacillus Calmette-Guérin on asthma.
Zhang GS; Wang PL; Huang HQ; Shen HH
Chin Med J (Engl); 2009 Mar; 122(5):577-83. PubMed ID: 19323911
[No Abstract] [Full Text] [Related]
10. Environmental strains of Mycobacterium avium interfere with immune responses associated with Mycobacterium bovis BCG vaccination.
Young SL; Slobbe L; Wilson R; Buddle BM; de Lisle GW; Buchan GS
Infect Immun; 2007 Jun; 75(6):2833-40. PubMed ID: 17371857
[TBL] [Abstract][Full Text] [Related]
11. Assessment of different formulations of oral Mycobacterium bovis Bacille Calmette-Guérin (BCG) vaccine in rodent models for immunogenicity and protection against aerosol challenge with M. bovis.
Clark S; Cross ML; Smith A; Court P; Vipond J; Nadian A; Hewinson RG; Batchelor HK; Perrie Y; Williams A; Aldwell FE; Chambers MA
Vaccine; 2008 Oct; 26(46):5791-7. PubMed ID: 18789366
[TBL] [Abstract][Full Text] [Related]
12. Atopic disorders among Estonian schoolchildren in relation to tuberculin reactivity and the age at BCG vaccination.
Annus T; Montgomery SM; Riikjärv MA; Björkstén B
Allergy; 2004 Oct; 59(10):1068-73. PubMed ID: 15355465
[TBL] [Abstract][Full Text] [Related]
13. Use of a tuberculin purified protein derivative--Asn-Ala-Asn-Pro conjugate in bacillus Calmette-Guérin primed mice overcomes H-2 restriction of the antibody response and avoids the need for adjuvants.
Lussow AR; Del Giudice G; Rénia L; Mazier D; Verhave JP; Verdini AS; Pessi A; Louis JA; Lambert PH
Proc Natl Acad Sci U S A; 1990 Apr; 87(8):2960-4. PubMed ID: 2183219
[TBL] [Abstract][Full Text] [Related]
14. Exposure to Mycobacterium avium can modulate established immunity against Mycobacterium tuberculosis infection generated by Mycobacterium bovis BCG vaccination.
Flaherty DK; Vesosky B; Beamer GL; Stromberg P; Turner J
J Leukoc Biol; 2006 Dec; 80(6):1262-71. PubMed ID: 16968819
[TBL] [Abstract][Full Text] [Related]
15. Disseminated Bacillus Calmette-Guerin infection after BCG vaccination.
Rezai MS; Khotaei G; Mamishi S; Kheirkhah M; Parvaneh N
J Trop Pediatr; 2008 Dec; 54(6):413-6. PubMed ID: 18593737
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of cell-mediated immune response in mice by whole HIV-1 gag in Mycobacterium bovis BCG as a live vaccine candidate.
Promkhatkaew D; Pinyosukhee N; Thongdeejaroen W; Sutthent R; Sawanpanyalert P; Warachit P
Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):113-22. PubMed ID: 19323043
[TBL] [Abstract][Full Text] [Related]
17. Is the mycobacteria-derived purified protein response in atopic asthmatic children different?
Kale HS; Taştan Y; Pinçe O; Altuncu E; Erginoz E
Int Arch Allergy Immunol; 2004 Nov; 135(3):229-34. PubMed ID: 15542937
[TBL] [Abstract][Full Text] [Related]
18. Response to neonatally thymectomized Holstein calves to bacille Calmette Guérin.
Snider TG; Pierce KR; Adams LG
Am J Vet Res; 1982 Aug; 43(8):1363-6. PubMed ID: 7049022
[TBL] [Abstract][Full Text] [Related]
19. A technique for intensifying BCG sensitivity.
Parmett SR; Klein E
J Med; 1975; 6(3-4):213-6. PubMed ID: 1104733
[TBL] [Abstract][Full Text] [Related]
20. Development of a Mycobacterium bovis intranasal challenge model in mice.
Logan KE; Gavier-Widen D; Hewinson RG; Hogarth PJ
Tuberculosis (Edinb); 2008 Sep; 88(5):437-43. PubMed ID: 18590980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
